Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of Temtokibart in Healthy Japanese Subjects
NCT05099133Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of temtokibart in atopic dermatitis (AD) (4 arms), sponsored by LEO Pharma. Primary endpoints: Area Under the Concentration-Time Curve from Pre-dose to Last Quantifiable Concentration, Area Under the Concentration-Time Curve Extrapolated to Infinite Time and 5 more. Started Nov 2021; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05099133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099133.